Brief: Cytodyn Announces Preliminary Results From 30 Mtnbc Patients Treated With Leronlimab. Decreases In Camls After 4 Doses Of Leronlimab Were Identified In Over 70% Of Patients And Were Associated With A 450% Significant Increase In Overall Survival At 12-Month Analysis
19/07/2021 13:43
July 19 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN ANNOUNCES PRELIMINARY RESULTS FROM 30 MTNBC
PATIENTS
TREATED WITH LERONLIMAB. DECREASES IN CAMLS AFTER 4 DOSES OF
LERONLIMAB WERE IDENTIFIED IN OVER 70% OF PATIENTS AND WERE
ASSOCIATED WITH A 450% SIGNIFICANT INCREASE IN OVERALL SURVIVAL
AT 12-MONTH ANALYSIS
Source text for Eikon: ID:nGNX9zn8df
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer